ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Renal function"

  • 2016 American Transplant Congress

    Is Ketorolac Really Safe for Donor Nephrectomy?

    K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.

    Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.

    Background. Ketorolac is a nonsteroidal anti-inflammatory drug used for postoperative pain management. The purpose of this study is to assess the impact of ketorolac after…
  • 2016 American Transplant Congress

    Comparison of Surgical Correction Techniques for Post-Kidney Transplantation Vesicoureteral Reflux.

    V. Turunç,1 A. Eroğlu,2 B. Tabandeh,1 H. Dheir,2 E. Basok,3 A. Erol.3

    1Department of General Surgery, Bahçesehir University, Faculty of Medicine, İstanbul, Turkey; 2Organ Transplantation Center, Göztepe Medical Park Hospital, İstanbul, Turkey; 3Department of Urology, Bahçesehir University, Faculty of Medicine, İstanbul, Turkey.

    PURPOSEThe aim of this study was to compare extravesical seromuscular tunnel lengthening technique with uretero-ureteral/pyelo-ureteral anastomosis techniques in post-transplant vesicoureteral reflux (VUR) management.MATERIALS AND METHODSWe…
  • 2016 American Transplant Congress

    Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.

    A. Ribeiro,1 M. Helfer,2 O. Costa,2 A. Viccari,1 R. Manfro.1,2

    1Division of Nephrology, Renal Transplant Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; 2School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

    Background. A high incidence of delayed graft function (DGF), after deceased donor kidney transplantation, occurs in Brazil and the reasons for such finding have not…
  • 2016 American Transplant Congress

    Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.

    F. Vincenti,1 J. Medina Pestana,2 M. Abouljoud,3 B. Bresnahan,4 V. Duro Garcia,5 L. Mulloy,6 K. Rice,7 L. Rostaing,8 C. Zayas,9 K. Calderon,10 U. Meier-Kriesche,10 M. Polinsky,10 H. Zhao,10 C. Larsen.11

    1UCSF, San Francisco; 2Hosp do Rim, Sao Paulo, Brazil; 3Henry Ford Hosp, Detroit; 4Med Coll of Wisconsin, Milwaukee; 5Hospital Dom Vicente Scherer, Porto Alegre, Brazil; 6Georgia Regents Univ, Augusta; 7Baylor Univ Med Ctr, Dallas; 8Univ Hosp and INSERM U563, IFR-BMT, Toulouse, France; 9Piedmont Hosp, Atlanta; 10BMS, Lawrenceville; 11Emory Univ Transplant Center, Atlanta.

    Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT, bela was associated with superior graft survival…
  • 2016 American Transplant Congress

    Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.

    R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.

    Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.

    Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…
  • 2016 American Transplant Congress

    Impact of BKV Subtype Distribution on BKV Nephropathy, Viremia, and Renal Outcome in Patients After Renal Transplantation.

    S. Anke,1 L. Silvia,1 H. Hermann,1 H. Albert,2 S. Corinna.2

    1Nephrology, Hannover Medical School, Hannover, Germany; 2Virology, Hannover Medical School, Hannover, Germany.

    Factors determining the course of BK viral (BKV) infection remain uncertain. We studied the role of BKV subtype distribution in BKV-infected patients after renal transplantation.-We…
  • 2016 American Transplant Congress

    Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.

    P. Tabrizian,1 M. Giacca,1 J. Prigoff,2 E. Chin,2 M. Palese,2 D. Herron,2 A. Arvelakis,1 D. LaPointe Rudow,1 S. Florman,1 R. Shapiro.1

    1Transplant, Recanati/Miller Transplantation Institute, New York, NY; 2Surgery, Mount Sinai Medical Center, New York, NY.

    Background: The benefit and short-term safety have been established in previous studies; however, the risk of bleeding and long-term renal impairment in patients undergoing donor…
  • 2016 American Transplant Congress

    AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.

    J. O'Leary,1 A. Philippe,2 H. Heidecke,2 R. Freeman,1 L. Jennings,1 R. Catar,2 G. Klintmalm,1 D. Dragun.2

    1Baylor Simmons Transplant Insttute, Baylor University Medical Center, Dallas, TX; 2Internal Medicine, Charite, Berlin, Germany.

    Angiotensin II Type-1 Receptor (AT1R) antibodies have been associated with pulmonary hypertension, renal allograft loss, and fibrosis progression in liver allograft recipients especially if combined…
  • 2016 American Transplant Congress

    Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

    J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.

    ELEVATE study group, Llobregat Catalunya, Spain.

    Background: Human leukocyte antigen (HLA) compatibility between donor and recipient is considered an important factor for graft outcomes. Compatibility is associated with a lower incidence…
  • 2016 American Transplant Congress

    Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.

    P. Bernhardt,1 G. Dong,2 P. Lopez,1 G. Hustache,1 G. Bader.1

    1Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hannover.

    Purpose:Cardiovascular disease (CVD) is one of the leading causes of death in liver transplant recipients (LTxRs). Impaired glomerular filtration rate (GFR) is a risk factor…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 27
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences